Blog

by Heidi Hagen and Subbu Viswanathan | March 3, 2020
This post is the third in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management) for personalized therapies, such as cell therapies, gene therapies, or neoantigen cancer vaccines. This series focuses…

by Heidi Hagen and Subbu Viswanathan | February 25, 2020
This post is the second in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management) for personalized therapies, such as cell therapies, gene therapies, or neoantigen cancer vaccines. This series focuses…

by Heidi Hagen and Subbu Viswanathan | February 25, 2020
This post is the first in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management) for personalized therapies, such as cell therapies, gene therapies, or neoantigen cancer vaccines. This series focuses…

by Heidi Hagen and Christophe Suchet | February 21, 2020
This post is the eighth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 19, 2020
This post is the seventh in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

Subscribe to our blog
Required
Required
Required
Required
Required
Required
Required